Under the deal, AmerisourceBergen will pay Walgreens Boots Alliance $6.275 billion in cash and 2 million shares of its common stock.
The companies said the transaction will allow AmerisourceBergen to provide more global support to pharmacies and drugmakers and let Walgreens Boots Alliance focus on strengthening its retail pharmacy businesses.
The deal is expected to close by the end of AmerisourceBergen’s 2021 fiscal year.
More articles on pharmacy:
Cuomo proposes making it a crime to skip ahead in COVID-19 vaccination line
Pfizer CMO departs; replacement named
FDA: Not enough data to halve COVID-19 vaccine doses